期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Platinum drugs:from Pt(Ⅱ)compounds,Pt(Ⅳ)prodrugs,to Pt nanocrystals/nanoclusters 被引量:7
1
作者 Xi Hu Fangyuan Li +1 位作者 nabila noor Daishun Ling 《Science Bulletin》 SCIE EI CSCD 2017年第8期589-596,共8页
Platinum(Pt) based drugs, such as cisplatin, are widely used as anti-cancer agents, but their severe adverse reactions and resistance of cancer patients have limited their board clinical use. For the last few decades,... Platinum(Pt) based drugs, such as cisplatin, are widely used as anti-cancer agents, but their severe adverse reactions and resistance of cancer patients have limited their board clinical use. For the last few decades, Pt(Ⅱ) compounds, Pt(Ⅳ) prodrugs as well as smart drug delivery systems have been developed to overcome these problems. However, most conventional strategies rely on the similar anti-cancer mechanism with cisplatin and consequently only achieve limited success. Recently, Pt nanocrystals/nanoclusters(Pt NCs), with a brand new anti-cancer mechanism, have shown a promising potential in targeted cancer therapy, especially in Pt resistance circumvention. This review is helpful to understand the research strategies of Pt drugs, particularly, the recent developments and medical applications of Pt NCs. 展开更多
关键词 Platinum Pt(Ⅱ) Pt(Ⅳ) Pt nanocrystals/nanoclusters Pt resistance Cancer therapy
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部